Valganciclovir HCl

Product introduction:

Valganciclovir HCl is a DNA polymerase inhibitor. After oral administration, it is rapidly hydrolyzed to ganciclovir under the action of intestinal mucosal cell esterase and liver esterase. Therefore, its pharmacodynamic characteristics are the pharmacodynamic characteristics of ganciclovir. Ganciclovir generates ganciclovir triphosphate under the phosphorylation of viral and intracellular enzymes. The latter competes with deoxyguanosine triphosphate (dGTP) as the substrate of viral DNA polymerase, so it inhibits the synthesis of viral DNA and produces anti CMV activity.

CAS：175865-59-5

Structural type:

Molecular formula: C₁₄H₂₃ClN₆O₅

Molecular weight: 390.82

Purpose:

It is used to prevent and treat CMV infection secondary to organ transplantation. The drug is a precursor of ganciclovir and a valine ester of active ganciclovir. After oral administration, it can be rapidly hydrolyzed into ganciclovir by phosphatase in intestinal and liver cells. Its antiviral spectrum and action mechanism are similar to ganciclovir, but its bioavailability is significantly higher than ganciclovir. Its bioavailability absorbed orally is 62.4%, 10 times that of ganciclovir, The toxicity is greatly reduced.